For example: KLE endometrial cancer cells, which harbor the oncogenic p53 mutation R175H, were resistant to AZD1775 + olaparib but sensitive to AZD1775 + gemcitabine, whereas both combinations were effective in Hec50 and OVCAR3 cells. This evidence concerns the gene TP53 and endometrial cancer.